ASTS rose +4.93% to $64.94 during regular trading, up from the prior session close of $61.89. Primary catalyst: French telecom Orange announced a partnership with AST SpaceMobile and its Satellite Connect Europe JV with Vodafone to advance direct-to-device satellite services.
DRAM (Roundhill Memory ETF) is up +3.05% to $63.46 during regular trading hours, from Monday's close of $61.58. The move is part of a sector-wide memory rally on AI demand, with Rosenblatt initiating SanDisk at Buy and RBC flagging an extended DRAM upcycle amid tight supply.
The Roundhill Memory ETF (DRAM) has gained roughly 10% over the past 30 days, recovering from a sharp mid-summer drawdown. DRAM is an actively managed thematic exchange-traded fund (ETF) concentrated in global memory and storage companies, led by Micron Technology, Samsung Electronics, and SK Hynix.
Nebius Group (NBIS) operates as an AI-focused infrastructure and cloud provider with a strategic alliance to NVIDIA Corporation, positioning it as a complementary player in the AI ecosystem. NVIDIA (NVDA) maintains leadership in graphics processing units (GPUs) and artificial intelligence accelerators, driving broader market influence through its hardware dominance and software ecosystem.
DELL fell -3.57% to $554.76 during regular trading, extending a multi-session AI-hardware selloff. Primary catalyst: renewed fears over AI-server margins as surging memory/DRAM costs squeeze ISG profitability.
JPMorgan Chase (JPM) fell -3.34% to $340.28 during Tuesday's regular session, versus Friday's close of $352.04. The drop came amid a broad financial-sector selloff, with bank stocks leading all S&P 500 sectors lower.
Black Titan (BTTC) fell -26.58% to roughly $0.575 during today's regular session, reversing a portion of Monday's +117.75% surge to $0.795. The decline is a pullback after a low-float, retail-driven squeeze that lifted volume to ~423M shares versus a ~5M average.
CMPX is trading down about -29% to roughly $1.29 during Tuesday's regular session, after initially plunging ~40% in premarket trading. The selloff followed news that the U.S. FDA recommended Compass run an additional trial to demonstrate a survival benefit for lead asset tovecimig before submitting a marketing application.
MU and SNDK both operate in the memory and storage semiconductor space, benefiting from AI-driven demand for high-performance chips. MU has delivered exceptional year-to-date returns exceeding 278% amid strong earnings growth and analyst optimism.
Arm Holdings (ARM) closed at $264.79 on September 11, 2026, up 4.17% on the day, but down roughly 2.6% over the trailing 30 days from $271.87. Shares remain sharply higher year to date at about 139%, though they trade well below the 52-week high of $452.70.
MAX is trading down -6.58% during the regular session, around $10.08 versus a $10.79 prior close on Sept. 21. The decline came with no single company-specific headline, pointing to broad-market weakness and profit-taking rather than a discrete catalyst.
GSHD is down -9.75% intraday, sliding to roughly $46.66 from Monday's $51.70 close during regular trading hours. The drop extends a steep multi-session selloff: shares already fell -5.22% on Monday and are off about -14% over the past week.
MMS operates in government services with exposure to federal and state contracts, while TOWN focuses on regional banking in the southeastern U.S. Recent market activity shows MMS maintaining relative stability amid contract renewals and operational efficiencies, contrasting with TOWN ’s sensitivity to interest rate environments and deposit growth trends.
CORT delivered robust Q2 2026 revenue growth of 32% year-over-year and raised full-year guidance amid the launch of its oncology asset. OPK shares have advanced approximately 34% year-to-date, supported by diversified operations and strategic financing moves.
Northwest Biotherapeutics (NWBO) has traded in a narrow range near $0.17 over the past 30 days, with the 30-day percentage change roughly flat at well under 10%. The stock's 52-week range spans roughly $0.14 to $0.34, reflecting the speculative nature of a pre-commercial biotechnology company.
AAR Corp. (AIR) gained +1.08% during the regular session, rising to about $117.51 from a prior close of $116.26. The move extended a multi-day rebound after a fresh bullish note this morning argued the stock's ~27% pullback from its August high was a buying opportunity, citing a $167 price target.
EVER is down -17.26% during regular trading, falling to $18.89 from Friday's $22.83 close. The decline extends a multi-session slide from roughly $24.47 on Sept. 15, with the stock near the lows intraday.
KPLT is trading down -8.84% to $8.04 during the regular session, extending Monday's -7.16% slide from $9.50 to $8.82. Primary catalyst: a Form S-3 shelf registration filed Sept 15, 2026, signaling potential new share issuance and stoking dilution concerns.
QNST is down -14.31% intraday, sliding from a prior close of $17.26 to about $14.79 during the regular session, on elevated volume. The decline extends a sustained slide — the stock was already off roughly -16% over the past month and has shed about -6.6% over the prior week.
The selected price target is $1.00 , a psychological milestone and the level typically required to satisfy Nasdaq's minimum bid price listing rule. Silexion is a clinical-stage biotech advancing SIL204, an RNA interference (RNAi) therapy for KRAS-driven pancreatic cancer, with a Phase 2/3 trial approved in Israel and Germany.